JP2019508017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508017A5 JP2019508017A5 JP2018531337A JP2018531337A JP2019508017A5 JP 2019508017 A5 JP2019508017 A5 JP 2019508017A5 JP 2018531337 A JP2018531337 A JP 2018531337A JP 2018531337 A JP2018531337 A JP 2018531337A JP 2019508017 A5 JP2019508017 A5 JP 2019508017A5
- Authority
- JP
- Japan
- Prior art keywords
- replication
- oncolytic virus
- defective
- antibody
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 244000309459 oncolytic virus Species 0.000 claims 41
- 239000013598 vector Substances 0.000 claims 20
- -1 CD31 Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 11
- 230000010076 replication Effects 0.000 claims 11
- 108700019146 Transgenes Proteins 0.000 claims 9
- 102000004127 Cytokines Human genes 0.000 claims 8
- 108090000695 Cytokines Proteins 0.000 claims 8
- 230000002950 deficient Effects 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 5
- 108010012236 Chemokines Proteins 0.000 claims 5
- 108700012434 CCL3 Proteins 0.000 claims 4
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 102100025221 CD70 antigen Human genes 0.000 claims 3
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 3
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 3
- 108090001007 Interleukin-8 Proteins 0.000 claims 3
- 102000004890 Interleukin-8 Human genes 0.000 claims 3
- 102000004473 OX40 Ligand Human genes 0.000 claims 3
- 108010042215 OX40 Ligand Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 102000002627 4-1BB Ligand Human genes 0.000 claims 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 2
- 102100037354 Ectodysplasin-A Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims 2
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 claims 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims 2
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 claims 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 2
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims 2
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 claims 2
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 claims 2
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 101150052608 SIVA1 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 2
- 108700012411 TNFSF10 Proteins 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 230000002101 lytic effect Effects 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100025594 Guided entry of tail-anchored proteins factor CAMLG Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims 1
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 101000932902 Homo sapiens Guided entry of tail-anchored proteins factor CAMLG Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 claims 1
- 101000984199 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 4 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 claims 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 101710093458 ICOS ligand Proteins 0.000 claims 1
- 102000039996 IL-1 family Human genes 0.000 claims 1
- 108091069196 IL-1 family Proteins 0.000 claims 1
- 102000039989 IL-17 family Human genes 0.000 claims 1
- 108091069193 IL-17 family Proteins 0.000 claims 1
- 108091069192 IL-2 family Proteins 0.000 claims 1
- 102000039990 IL-2 family Human genes 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 claims 1
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 claims 1
- 102100025555 Leukocyte immunoglobulin-like receptor subfamily A member 4 Human genes 0.000 claims 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims 1
- 102100039564 Leukosialin Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 102100028762 Neuropilin-1 Human genes 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 241000837158 Senecavirus A Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100026966 Thrombomodulin Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 1
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 108700014844 flt3 ligand Proteins 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000937 inactivator Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960003816 muromonab-cd3 Drugs 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 229950002610 otelixizumab Drugs 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522334.0A GB201522334D0 (en) | 2015-12-17 | 2015-12-17 | Method |
| GB1522334.0 | 2015-12-17 | ||
| GBGB1607463.5A GB201607463D0 (en) | 2016-04-29 | 2016-04-29 | Method |
| GB1607463.5 | 2016-04-29 | ||
| GBGB1617207.4A GB201617207D0 (en) | 2016-10-10 | 2016-10-10 | Method |
| GB1617206.6 | 2016-10-10 | ||
| GBGB1617206.6A GB201617206D0 (en) | 2016-10-10 | 2016-10-10 | Method |
| GB1617207.4 | 2016-10-10 | ||
| PCT/EP2016/081818 WO2017103291A1 (en) | 2015-12-17 | 2016-12-19 | Virus encoding an anti-tcr-complex antibody or fragment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508017A JP2019508017A (ja) | 2019-03-28 |
| JP2019508017A5 true JP2019508017A5 (cg-RX-API-DMAC7.html) | 2020-02-06 |
Family
ID=57794239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531336A Active JP7064437B2 (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス |
| JP2018531337A Ceased JP2019508017A (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531336A Active JP7064437B2 (ja) | 2015-12-17 | 2016-12-19 | 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス |
Country Status (19)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3021859T3 (cg-RX-API-DMAC7.html) | 2013-10-25 | 2018-04-28 | ||
| CA2977660A1 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| JP6936153B2 (ja) | 2015-04-17 | 2021-09-15 | メモリアル スローン ケタリング キャンサー センター | Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用 |
| EA037611B1 (ru) | 2015-04-30 | 2021-04-21 | Псайоксус Терапьютикс Лимитед | Онколитический аденовирус, кодирующий белок b7 |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| AU2017222686B2 (en) | 2016-02-25 | 2021-12-23 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| EP3419662A4 (en) | 2016-02-25 | 2019-09-18 | Memorial Sloan Kettering Cancer Center | HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| RU2021127872A (ru) * | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| WO2019173334A1 (en) * | 2018-03-05 | 2019-09-12 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| CN111989397A (zh) * | 2018-03-30 | 2020-11-24 | 藤堂具纪 | 肿胀发生抑制型溶瘤病毒 |
| AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| WO2020050630A1 (ko) | 2018-09-07 | 2020-03-12 | 주식회사 케이티 | 비면허 대역에서 무선 통신을 수행하는 방법 및 장치 |
| JP7480126B2 (ja) | 2018-09-15 | 2024-05-09 | メモリアル スローン ケタリング キャンサー センター | がん免疫療法のための、組換えポックスウイルス |
| WO2020143221A1 (zh) * | 2019-01-07 | 2020-07-16 | 四川安可康生物医药有限公司 | 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用 |
| US20200215133A1 (en) * | 2019-01-07 | 2020-07-09 | Sichuan Oncocare Biopharmaceutical, Inc. | Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| KR20220093103A (ko) * | 2019-09-13 | 2022-07-05 | 어드메어 테라퓨틱스 소사이어티 | 항종양용해 바이러스 항원 항체 및 이의 사용 방법 |
| CN114729305A (zh) * | 2019-10-17 | 2022-07-08 | 苏州丹罗医药有限公司 | 用于免疫治疗的嵌合抗原受体、制备方法及其应用 |
| US20230086531A1 (en) * | 2020-03-04 | 2023-03-23 | Bioeclipse Therapeutics, Inc. | Methods of manufacturing activated immune cells |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| CN112063588A (zh) * | 2020-08-13 | 2020-12-11 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| EP4204004A4 (en) * | 2020-08-31 | 2024-11-27 | Exuma Biotech Corp. | ANTI-IDIOTYPE COMPOSITIONS AND METHODS OF USE |
| KR20220105139A (ko) * | 2021-01-19 | 2022-07-26 | 광주과학기술원 | Igsf4의 막 관통 도메인을 발현하는 t 세포 및 이의 이용 |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| JP7697147B2 (ja) * | 2021-06-03 | 2025-06-23 | 上▲海▼允英生物医▲薬▼科技有限公司 | 腫瘍溶解性ウイルスベクターおよびその適用 |
| CN113355296A (zh) * | 2021-06-07 | 2021-09-07 | 中国人民解放军空军军医大学 | 一种表达人ccl19的重组溶瘤新城疫病毒及其应用 |
| CN116024175A (zh) * | 2021-10-27 | 2023-04-28 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| IL313740A (en) | 2021-12-23 | 2024-08-01 | Helsingin Yliopisto | A method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells |
| CN114891126B (zh) * | 2022-06-23 | 2023-05-09 | 上海安库生医生物科技有限公司 | 一种靶向fshr和cd3分子的双结合蛋白及其应用 |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| CZ287157B6 (en) | 1993-07-13 | 2000-10-11 | Rhone Poulenc Rorer Sa | Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| US6420524B1 (en) | 1997-02-20 | 2002-07-16 | Johns Hopkins University School Of Medicine | Gain of function mutations in ATP-dependent transposition proteins |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| AU9603898A (en) | 1997-10-09 | 1999-05-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
| CA2354024C (en) | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1155120B1 (fr) | 1999-02-22 | 2006-07-05 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| JP2002541792A (ja) | 1999-04-09 | 2002-12-10 | アベンテイス・フアルマ・ソシエテ・アノニム | 感染性の組換えアデノウイルスの保存用組成物 |
| DK1550722T3 (da) | 1999-05-17 | 2007-10-08 | Crucell Holland Bv | Rekombinant human adenovirus serotype 35 |
| AU5464000A (en) | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| ES2254359T3 (es) | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| AU2001265154A1 (en) | 2000-05-31 | 2001-12-11 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| ATE385504T1 (de) | 2000-06-06 | 2008-02-15 | Bristol Myers Squibb Co | Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| EP1348030B1 (en) | 2001-01-04 | 2009-11-25 | Wadell, Göran | Viral vector for gene therapy |
| US20050175589A1 (en) | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| EP1470233A1 (en) | 2002-02-01 | 2004-10-27 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with pods |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| US20040213764A1 (en) | 2003-03-28 | 2004-10-28 | William Wold | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| WO2005010149A2 (en) | 2003-07-18 | 2005-02-03 | Onyx Pharmaceuticals, Inc. | Subgroup b adenoviral vectors for treating disease |
| KR20120125634A (ko) | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| DE602005025340D1 (de) | 2004-05-26 | 2011-01-27 | Bayer Schering Pharma Ag | Chimäre adenoviren zur verwendung in der krebsbehandlung |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| JP2008511336A (ja) | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| US20090208924A1 (en) | 2004-12-01 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Generation of Replication Competent Viruses for Therapeutic Use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| JP2008050051A (ja) | 2006-08-28 | 2008-03-06 | Bokuson Uesuto:Kk | ディスペンスヘッド |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
| WO2009143610A1 (en) | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| RU2547600C2 (ru) | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011043719A1 (en) | 2009-10-05 | 2011-04-14 | Ya-Fang Mei | Replicating viral vectors for gene therapy |
| WO2012024351A2 (en) | 2010-08-16 | 2012-02-23 | Salk Institute For Biological Studies | Adenoviral assembly method |
| CA2812093A1 (en) | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| EA030147B1 (ru) | 2011-08-23 | 2018-06-29 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| EP2780020A4 (en) | 2011-11-14 | 2016-03-02 | Regenerative Sciences Llc | SUSPENDED PARTICLE DISTRIBUTION SYSTEMS AND METHODS |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| CN105407902A (zh) | 2013-03-05 | 2016-03-16 | 贝勒医学院 | 溶瘤病毒 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| GB201318793D0 (en) | 2013-10-24 | 2013-12-11 | Plaquetec Ltd | Vascular Biomarkers |
| NO3021859T3 (cg-RX-API-DMAC7.html) | 2013-10-25 | 2018-04-28 | ||
| AU2014352749A1 (en) | 2013-11-22 | 2016-06-09 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| AU2015240595B2 (en) * | 2014-04-03 | 2020-02-27 | Igm Biosciences, Inc. | Modified J-chain |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| US20170313990A1 (en) | 2014-08-27 | 2017-11-02 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| US11485791B2 (en) | 2015-03-17 | 2022-11-01 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies |
| EA037611B1 (ru) | 2015-04-30 | 2021-04-21 | Псайоксус Терапьютикс Лимитед | Онколитический аденовирус, кодирующий белок b7 |
| WO2017103291A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Virus encoding an anti-tcr-complex antibody or fragment |
| WO2017161360A2 (en) | 2016-03-18 | 2017-09-21 | Nant Holdings Ip, Llc | Multimodal vector for dendritic cell infection |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| SG11201901716TA (en) | 2016-08-29 | 2019-03-28 | Psioxus Therapeutics Ltd | Adenovirus armed with bispecific t cell engager (bite) |
| EP3529361B1 (en) | 2016-10-20 | 2021-03-24 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-12-19 WO PCT/EP2016/081818 patent/WO2017103291A1/en not_active Ceased
- 2016-12-19 CN CN201680074772.7A patent/CN108697745A/zh active Pending
- 2016-12-19 JP JP2018531336A patent/JP7064437B2/ja active Active
- 2016-12-19 MY MYPI2018702073A patent/MY193281A/en unknown
- 2016-12-19 BR BR112018012179A patent/BR112018012179A2/pt not_active IP Right Cessation
- 2016-12-19 IL IL260027A patent/IL260027B/en unknown
- 2016-12-19 SG SG11201805136TA patent/SG11201805136TA/en unknown
- 2016-12-19 MX MX2018007249A patent/MX2018007249A/es unknown
- 2016-12-19 AU AU2016372576A patent/AU2016372576A1/en not_active Abandoned
- 2016-12-19 SG SG11201805137XA patent/SG11201805137XA/en unknown
- 2016-12-19 US US16/062,024 patent/US11155622B2/en active Active
- 2016-12-19 US US16/062,036 patent/US11970536B2/en active Active
- 2016-12-19 EA EA201891022A patent/EA201891022A1/ru unknown
- 2016-12-19 EP EP16825728.5A patent/EP3389683B8/en active Active
- 2016-12-19 AU AU2016369485A patent/AU2016369485B2/en active Active
- 2016-12-19 CN CN201680076032.7A patent/CN108697746A/zh active Pending
- 2016-12-19 BR BR112018012180A patent/BR112018012180A2/pt not_active IP Right Cessation
- 2016-12-19 KR KR1020187020442A patent/KR102857666B1/ko active Active
- 2016-12-19 DK DK16825727.7T patent/DK3389682T3/da active
- 2016-12-19 KR KR1020187020443A patent/KR20180108590A/ko not_active Withdrawn
- 2016-12-19 WO PCT/EP2016/081817 patent/WO2017103290A1/en not_active Ceased
- 2016-12-19 CA CA3006859A patent/CA3006859A1/en active Pending
- 2016-12-19 JP JP2018531337A patent/JP2019508017A/ja not_active Ceased
- 2016-12-19 EP EP16825727.7A patent/EP3389682B1/en active Active
- 2016-12-19 EA EA201891021A patent/EA201891021A1/ru unknown
-
2018
- 2018-05-28 ZA ZA2018/03523A patent/ZA201803523B/en unknown
- 2018-06-12 CO CONC2018/0005945A patent/CO2018005945A2/es unknown
- 2018-06-14 IL IL260033A patent/IL260033A/en unknown
- 2018-06-14 CL CL2018001611A patent/CL2018001611A1/es unknown
- 2018-06-18 PH PH12018501291A patent/PH12018501291A1/en unknown
-
2023
- 2023-11-27 US US18/520,030 patent/US20240247061A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508017A5 (cg-RX-API-DMAC7.html) | ||
| JP2019502379A5 (cg-RX-API-DMAC7.html) | ||
| Eriksson et al. | Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment | |
| CN108431210B (zh) | 培养细胞的方法及用于该方法的试剂盒和设备 | |
| JP2018514199A5 (cg-RX-API-DMAC7.html) | ||
| Bonilla et al. | The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses | |
| SI3021859T1 (en) | Oncolytic adenoviruses equipped with heterologous genes | |
| Apostolidis et al. | The dysregulation of cytokine networks in systemic lupus erythematosus | |
| Fann et al. | Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T‐cell aging | |
| CN115003700B (zh) | 促实体瘤浸润的增强型cart细胞及其制备方法和细胞药物 | |
| JP2019534036A5 (cg-RX-API-DMAC7.html) | ||
| Scheller et al. | Immunoreceptor engineering and synthetic cytokine signaling for therapeutics | |
| Koch et al. | Role of interferon-λ in allergic asthma | |
| Yamada et al. | Features of the cytokines secreted by adult T cell leukemia (ATL) cells | |
| CN111032850A (zh) | 寡聚粒子试剂及其使用方法 | |
| JP2018531035A6 (ja) | 細胞を培養するための方法ならびにそのためのキットおよび装置 | |
| WO2015155370A4 (en) | Group b adenovirus modified in the e4orf4 region | |
| Pletnev et al. | Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20 | |
| JP2019500012A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525364A5 (cg-RX-API-DMAC7.html) | ||
| AU2018277294A1 (en) | Oncolytic virus and method | |
| WO2021223376A1 (zh) | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 | |
| Sebastian et al. | Signal transduction around thymic stromal lymphopoietin (TSLP) in atopic asthma | |
| CN113811602A (zh) | 一种可助推免疫细胞在体内扩增的佐剂 | |
| JP2019524111A5 (cg-RX-API-DMAC7.html) |